BRIEF-Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Reuters
14 Jan

Jan 14 (Reuters) - VistaGen Therapeutics Inc :

* VISTAGEN ANNOUNCES POSITIVE RESULTS FROM EXPLORATORY PHASE 2A STUDY OF PH284 IN CANCER CACHEXIA

* VISTAGEN ANNOUNCES POSITIVE RESULTS FROM EXPLORATORY PHASE 2A STUDY OF PH284 IN CANCER CACHEXIA

* VISTAGEN THERAPEUTICS INC - PH284 DEMONSTRATES NO SERIOUS ADVERSE EVENTS

* VISTAGEN THERAPEUTICS INC - PHASE 2A STUDY EVALUATES EFFICACY, SAFETY, AND TOLERABILITY OF PH284

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

no data

No relevant data is available

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."